FACTORS ASSOCIATED WITH SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM

Authors

  • Yazidi М. University of Tunis el manar
  • Essayeh S. University of Tunis El Manar
  • Oueslati I. University of Tunis El Manar
  • Khessairi N. University of Tunis El Manar
  • Chaker F. University of Tunis El Manar
  • Chihaoui M. University of Tunis El Manar

DOI:

https://doi.org/10.21856/j-PEP.2022.2.09

Keywords:

primary hyperparathyroidism, severe hypercalcemia, parathyroid hormone, parathyroid carcinoma, surgery

Abstract

Objectives: To determine the factors associated with severe hypercalcemia (SH) in primary hyperparathyroidism (PHPT).

Methods: This is a retrospective study involving the medical records of 123 patients with PHPT collected over a period of 20 years. The patients were subdivided into two groups according to their highest calcium level: ≥ 3.25 mmol/l (SH) or < 3.25 mmol/l (Moderate hypercalcemia). The two groups were compared by univariate and multivariate analysis according to their socio-demographic, clinical and paraclinical parameters.

Results: The prevalence of SH was 35.8%. Clinical factors associated with SH were abdominal pain (p=0.02), vomiting (p=0.05), and acute pancreatitis (p=0.005). Biological factors associated with SH were higher PTH level (p=0.001) and vitamin D deficiency (p=0.01). The parathyroid adenoma size was significantly higher and parathyroid carcinoma was more frequent in the SH group (p=0.001 and p=0.06, respectively). After multivariate analysis, the factors independently associated with SH were a parathyroid adenoma size ≥20 mm and a PTH level ≥300 pg /ml (adjusted odds ratios = 12 and 7.7 respectively).

Conclusion: In patients with PHPT, a PTH level ≥300 pg/ml and a parathyroid adenoma size ≥20 mm are the main predictors of the onset of SH. Acute pancreatitis and parathyroid carcinoma appear to be more common in these forms of PHPT, requiring prompt surgical management after medical preparation.

References

Fraser WD. Lancet 2009;374: 145-158.

Pepe J, Cipriani C, Pilotto R, et al. J Endocrinol Invest 2011;34(7): S40-S44.

Cannon J, Lew JI, Solórzano CC. Surgery 2010;148(4): 807-812.

Guidon C. Hypercalcémies sévères: Encycl Med Chir. (Anesthesie-Reanimation), Paris, 2016: 11p.

Shazia A, Gayatri K, Devin S. Am J Med 2015;128(3): 239-245.

Hanley DA, Cranney A, Jones G, et al. Can Med Assoc J 2010;182(12): 610‑618.

World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, available at: https://apps.who.int/iris/handle/10665/39142

Lew JI, Soloranzo CC, Irvin GL, et al. 3rd. Arch Surg 2006;141(7): 696-699.

Phitayakorn R, Machenry CR. J Am Coll Surg 2008;206(3): 1106-1115.

Starker LF, Björklund P, Theoharis C, et al. World J Surg 2010;35(2): 331-335.

Beck W, Lew JI, Solórzano CC. J Surg Res 2011;171(2): 404-408.

Lowell AJ, Bushman NM, Wang X, et al. J Surg Res 2017;217: 252-257.

Gücek Haciyanli S, Acar N, Ogür E, et al. Ann R Coll Surg Engl 2020;102(5): 363-368.

Arya AK, Bhadada SK, Mukhjee S. Indian J Med Res 2018;148(6): 721-727.

Minisola S, Romagnoli E, Carnevale V, Scillitani A. Acute management of hypercalcemia. In: Bilezikian JP, dir. The Parathyroids: basic and clinical concepts, New York, 2014: 617-629.

Yan H, Calcatera N, Moo-Young TA, et al. Am J Surg 2019;217(3): 437-440.

Davies M, Heys SE, Selby PL. J Clin Endocrinol Metab 1997;82: 209-212.

Malabanan A, Veroniks IE, Holick MF. Lancet 1998;351: 805-806.

Boone D, Politz D, Lopez J, et al. Surgery 2017;161(1): 98-106.

Amaral LM, Queiroz DC, Marques TF, et al. J Osteoporos 2012;2012: 1-5.

Walker MD, Nickolas T, Kepley A. J Clin Endocrinol Metab 2014;99(5): 1885-1892.

Cormier C, Souberbielle JC, Kahan A. Rev Med Interne 2004;25(5): S560-S567.

Randhawa PS, Mace AD, Nouraei SA. Clin Otolaryngol 2007;32: 179-184.

Hamidi S, Aslani A, Nakhjavani M. ANZ J Surg 2006;76: 882-885.

Gasparri G, Camandona M, Mullineris B, et al. Ann Ital Chir 2004;75: 321-324.

Erovic BM, Goldstein DP, Kim D, et al. Head Neck 2013;35(1): 35-39.

Betea D, Potorac I, Beckers A. Ann Endocrinol 2015;76: 169-177.

Schulte KM, Talat N. Nat Rev Endocrinol 2012;8: 612-622.

Do Cao C, Aubert S, Trinel C, et al. Ann Endocrinol 2015;76: 165-168.

Downloads

Published

2022-06-09

How to Cite

Yazidi, M., Essayeh, S., Oueslati, I., Khessairi, N., Chaker, F., & Chihaoui, M. (2022). FACTORS ASSOCIATED WITH SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM. Problems of Endocrine Pathology, 79(2), 60-65. https://doi.org/10.21856/j-PEP.2022.2.09

Issue

Section

CLINICAL ENDOCRINOLOGY